Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

CeMM Featured PhD Programmes
University College London Featured PhD Programmes
University of Oxford Featured PhD Programmes
University of Sussex Featured PhD Programmes
University College London Featured PhD Programmes

Stratification of response to treatment in schizophrenia

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Prof T Bjourson
    Dr E Murray
  • Application Deadline
    Applications accepted all year round

About This PhD Project

Project Description

Schizophrenia is a debilitating disorder characterized by positive, negative and cognitive symptoms.
Affecting approximately 1% of the population worldwide, schizophrenia places significant burden on society
through direct healthcare costs and indirect costs associated with loss of productivity (1-2).
Schizophrenia is treated with antipsychotic medications but there is a high level of inter-individual variability
in treatment efficacy and adverse events (3). In fact, only 50% of patients respond to initial treatment with
antipsychotic medications and clinicians rely on a trial and error approach to determine the most effective
treatment for a particular individual.
There is growing evidence that inflammation is implicated in the aetiology of schizophrenia and that
circulating cytokine levels are predictive of treatment response (4-6). Genetic and epigenetic variation may
also play a role in determining antipsychotic response, including changes in genes with known immune
function (7-8).
The goal of this PhD project is to stratify patients based on their response to treatment to determine
whether there are clinical, genetic/epigenetic and inflammatory profiles that are associated with treatment
outcome, and whether these profiles can be used to predict treatment response at the time of diagnosis.

FindAPhD. Copyright 2005-2018
All rights reserved.